RepliCel Life Sciences (TSE:RP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
RepliCel Life Sciences has announced the sale of its assets and licensing of patent rights to 1456390 B.C. Ltd, a company controlled by RepliCel’s CEO Andrew Schutte. The deal is seen as the best path forward for maximizing shareholder return and commercializing the assets. The agreement includes an 8% royalty on gross profits from the commercialized products, promising a potential value increase for shareholders.
For further insights into TSE:RP stock, check out TipRanks’ Stock Analysis page.